Research programme: cancer therapeutics - Stainwei Biotech

Drug Profile

Research programme: cancer therapeutics - Stainwei Biotech

Alternative Names: M23; P16

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Stainwei Biotech
  • Class Monoclonal antibodies
  • Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
  • 21 Apr 2010 Pharmacodynamics data from a preclinical trial in Cancer presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
  • 29 May 2009 Preclinical trials in Cancer in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top